Role of oxidative stress and antioxidant defense biomarkers in neurodegenerative diseases
Functional complications of obesity got better and stayed better
I think a lot of companies we're going to see maybe shifting away from this custom approach because they are afraid that the FDA could come in any day and shut them down and say you can't do this anymore. George Ball, Indiana University associate professor of operations and decision technologies, has a different take on the situation
At the end of 88 weeks, their weight was clearly higher than the active treatment group, but they were still 9.5% below their starting weight
The most commonly reported flu-like manifestations include: Nausea and general malaise the most frequent side effect, with incidence varying by product and dose (ranging from approximately 15-40% depending on the specific medication and dosage) Fatigue and low energy levels often described as feeling generally unwell or 'run down' Headaches ranging from mild to moderate intensity Dizziness or light-headedness particularly when standing up quickly, which may reflect dehydration or, in patients also taking insulin or sulfonylureas, possible hypoglycaemia Loss of appetite which, whilst therapeutically beneficial, can contribute to feeling unwell Mild gastrointestinal upset including occasional vomiting or abdominal discomfort These symptoms typically emerge because GLP-1 medications significantly alter gastrointestinal function and metabolic processes
